Contributing to researchers' clinical understanding of SARS-CoV-2 infection, Post-Acute COVID Syndrome (PACS), and systemic recovery

Members of the NMR International COVID-19 Research Network have published grounding breaking research showing how NMR spectroscopy has played a key role in our growing understanding of the long-term systemic effects of SARS-CoV-2 infection, using metabolic phenotyping.

There is a growing body of research demonstrating that an individual’s metabolic ‘biosignature’, measured through nuclear magnetic resonance (NMR*) spectroscopy, can possibly provide reliable insight for researching into the severity of COVID-19 disease, patient progress towards recovery, and individual risk of developing Post-Acute COVID Syndrome (PACS), also known as ‘long COVID’.

Researchers at the Australian National Phenome Centre (ANPC), Murdoch University, previously described the concept of phenoconversion — the change from a normal or healthy state to a disordered pathophysiological state or overt pathology — characterized by a series of rapid localized and systemic effects in metabolism and physiology. A range of metabolic biomarkers that are specific to disease state detection and measurement of severity can be analyzed, and results from NMR* measurements on plasma has the potential to provide researchers with deep insights into a range of pathophysiological processes.

This white paper reviews several key publications that have identified biomarkers of metabolic changes associated with PACS. These studies have led to a more advanced understanding of how a person’s metabolic phenotype can influence their likelihood of developing PACS and, eventually, contribute to better patient outcomes.

*Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures

In this white paper, we review 13 publications, and you can learn how,

  • NMR* spectroscopy has played a key role in modern disease research.
  • NMR* methods have the potential to help researchers revealing reliable insights into:

    - disease severity
    - progress towards recovery
    - risk of developing Post-Acute COVID Syndrome (PACS), or ‘Long COVID’
    - early-stage secondary organ damage
    - risk of developing a secondary disease.

Download the white paper to find out more

Input value is invalid.

Contact Information

Please enter your first name
Please enter your last name
Please enter a valid e-mail address
Please enter your Company/Institution

Privacy Settings

Please accept the Terms and Conditions
Please accept the Terms and Conditions